Side by side
Orforglipron vs Survodutide
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Orforglipron | Survodutide | |
|---|---|---|
| What it is | The first GLP-1 pill that is a true small molecule. Approved in April 2026, and taken any time of day with no food or water restrictions. | A GLP-1 and glucagon dual agonist in phase 3, and one of the more advanced candidates for fatty liver disease rather than weight alone. |
| EvidenceHow much human evidence exists, not how well it works. | Approved | Clinical trials |
| Regulatory statusReviewed 2026-08-18 | Approved by the FDA on 1 April 2026 as Foundayo, for chronic weight management in adults with obesity, or overweight with a weight-related condition. The first non-peptide, small-molecule GLP-1 receptor agonist approved for weight loss. | Not approved in any jurisdiction. In phase 3 development for obesity and for metabolic dysfunction-associated steatohepatitis. Anything sold as survodutide today is a research chemical. |
| Routes | Oral | Subcutaneous |
| Half-life | 30 hours | 150 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $40.00/mg | $4.87/mg |
| Median per mg | $40.00/mg | $10.00/mg |
| Vendors with a price | 1 | 12 |
| Storage once mixed | Not applicable. This is a tablet. | Refrigerated at 2–8 °C. Do not freeze once mixed. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.